Incyte's Immuno-oncology and Targeted Therapy Clinical Portfolio to be Featured in More than 15 Abstracts at the 2017 ASCO Annual Meeting
Data presentations will include six abstracts from the ECHO-202/KEYNOTE-037 trial (NCT02178722), evaluating the safety and efficacy of epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy, in various tumor types (two oral presentations, three poster discussions and one poster session). KEYTRUDA is marketed by Merck (known as MSD outside
Additionally, data from ECHO-204 (NCT02327078) evaluating the safety and efficacy of epacadostat in combination with Opdivo® (nivolumab) have been accepted as an oral presentation.
“These abstracts highlight the depth and potential of our growing clinical development portfolio of both immuno-oncology and targeted therapies,” said
Select key abstracts and presentations include:
Immuno-oncology abstracts
Efficacy and Safety of Epacadostat Plus Pembrolizumab Treatment of NSCLC: Preliminary Phase 1/2 Results of ECHO-202/KEYNOTE-037 (Abstract #9014, poster discussion)
Saturday, June 3, 2017 , 8:00 –11:30 a.m. CT , Hall A, Poster Board 340; Discussion 3:00 –4:15 p.m. CT , Hall D2
Epacadostat Plus Pembrolizumab in Patients with Advanced RCC: Preliminary Phase 1/2 Results from ECHO-202/KEYNOTE-037 (Abstract #4515, poster discussion)
Sunday, June 4, 2017 , 8:00 –11:30 a.m. CT , Hall A, Poster Board #193; Discussion 11:30 –12:45 p.m. CT ,Arie Crown Theater
Efficacy/Safety of Epacadostat Plus Pembrolizumab in Triple-Negative Breast Cancer and Ovarian Cancer: Phase 1/2 ECHO-202 Study (Abstract #1103, poster session)
Sunday, June 4, 2017 , 8:00 –11:30 a.m. CT , Hall A, Poster Board #95
Epacadostat Plus Pembrolizumab in Patients with Advanced Urothelial Carcinoma: Preliminary Phase 1/2 Results of ECHO-202/KEYNOTE-037 (Abstract #4503, oral presentation)
Monday, June 5, 2017 , 8:36 –8:48 a.m. CT ,Arie Crown Theater
Safety of Epacadostat 100 mg BID Plus Pembrolizumab 200 mg Q3W in Advanced Solid Tumors: Phase 2 Data from ECHO-202/KEYNOTE-037 (Abstract #3012, poster discussion)
Monday, June 5, 2017 , 8:00 –11:30 a.m. Hall A, Poster Board #107; Discussion 4:45 –6:00 p.m. CT , Hall D1
Epacadostat Plus Nivolumab in Patients with Advanced Solid Tumors: Preliminary Phase 1/2 Results of ECHO-204 (Abstract #3003, oral presentation)
Monday, June 5, 2017 , 2:15 –2:27 p.m. CT , Hall D1
CX-1158-101: A first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients with solid tumors (Abstract #3005, oral presentation)
Monday, June 5, 2017 ,2:39 p.m. –2:51 p.m. CT , Hall D1
Epacadostat Plus Pembrolizumab in Patients with SCCHN: Preliminary Phase 1/2 Results from ECHO-202/KEYNOTE-037 (Abstract #6010, oral presentation)
Tuesday, June 6, 2017 , 8:12 –8:24 a.m. CT , S100a
Targeted therapy abstract
Ongoing Phase 1/2 Study of INCB050465 for Relapsed/Refractory (R/R) B-Cell Malignancies (CITADEL-101) (Abstract #7530, poster session)
Monday, June 5, 2017 , 8:00 –11:30 a.m. CT , Hall A, Poster Board #292
Full session details and data presentations at the
About
Follow @
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data regarding the Company’s development portfolio and the potential effectiveness of such portfolio, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company’s development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks detailed from time to time in the Company’s reports filed with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20170420006249/en/
Source:
Incyte Corporation
Media
Catalina Loveman, +1 302-498-6171
cloveman@incyte.com
or
Investors
Michael Booth, DPhil, +1 302-498-5914
mbooth@incyte.com